MedComm | Intermedin promotes vessel fusion by inducing VE‐cadherin accumulation at potential fusion sites and to achieve a dynamic balance between VE‐cadherin‐complex dissociation/reconstitution

A closed vascular system is always established by vessel fusion. However, it has been an unsolved mystery that how vessel fusion happened in this process. In this study, Lingmiao Kong et al reported t....



MedComm | Metabolism in tumor microenvironment: Implications for cancer immunotherapy

Recently, tumor immunotherapy based on T cells has given patients new hope, however, its problem of low response rate sometimes leads to poor prognosis. That means new strategies sensitizing cancer im....



MedComm | Engineered biomaterials for cancer immunotherapy

Cancer immunotherapy has recently drawn much attention for its potentiality on clinic. However, the problem of side effects induced by poor selectivity and high doses still exists. In this review, Lul....



MedComm | Plasma pTau181 as a biomarker for Alzheimer's disease

Alzheimer's disease (AD) is one of the most difficult neurological disorders, because there are no means of biomarkers to predict the disease progression, nor is there a cure. Recently, on Nature Medi....



MedComm | The challenges of the COVID‐19 pandemic: Approaches for the elderly and those with Alzheimer's disease

The COVID-19 outbreak has brought challenges to societies around the globe, especially for some special communities. In this article, Qing Zhang et al reviewed some unique challenges the elderly and p....



MedComm - Plasma therapy cured a COVID‐19 patient with long duration of viral shedding for 49 days

COVID-19 has spread worldwide since it began in late 2019, becoming a threat to global health. Recently, Li Tan et al reported a special case of a family cluster with a mild type of COVID‐19, in which....